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Venous thromboembolic disease in childhood is a multifactorial disease. Risk factors 
include acquired clinical risk factors such as a central venous catheter and underlying 
disease and inherited thrombophilia. Inherited thrombophilia is defined as a genetically 
determined tendency to develop venous thromboembolism. In contrast to adults, 
acquired clinical risk factors play a larger role than inherited thrombophilia in the develop-
ment of thrombotic disease in children. The contributing role of inherited thrombophilia 
is not clear in many pediatric thrombotic events, especially catheter-related thrombosis. 
Furthermore, identification of inherited thrombophilia will not often influence acute man-
agement of the thrombotic event as well as the duration of anticoagulation. In some 
patients, however, detection of inherited thrombophilia may lead to identification of other 
family members who can be counseled for their thrombotic risk. This article discusses 
the potential arguments for testing of inherited thrombophilia, including factor V Leiden 
mutation, prothrombin mutation, and deficiencies of antithrombin, protein C, or protein S 
and suggests some patient groups in childhood, which may be tested.
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inTRODUCTiOn
Venous thromboembolism (VTE) is increasingly recognized in children. In the 1990s, the annual 
incidence was estimated to be 0.07–0.14 per 10,000 children (1, 2). Since then, studies showed more 
and more children developing thromboembolic complications as a result of improved diagnosis, 
increased survival of children with severe underlying diseases, and increased use of invasive pro-
cedures and instruments such as central venous catheters. From 2001 to 2007, diagnosis of VTE 
increased from 34 to 58 cases per 10,000 hospital admissions in the United States (3). This increase 
was observed in all age categories. Neonates and adolescents have the greatest risk for VTE (4). It is 
a serious disease, which leads to mortality and morbidity. The mortality rate is about 2%. Morbidity 
includes lack of thrombus resolution in 50% of the patients and the development of post thrombotic 
syndrome in about 30% of the patients (5).
In contrast to adults, most of the venous thrombi in children are associated with clinical risk fac-
tors. In neonates, more than 90% of the thrombi are catheter related. In older children, catheters are 
important risk factors as well, as about 50% of VTE are associated with central venous catheters (4). 
Abbreviations: VTE, venous thromboembolism; FVL, factor V Leiden mutation; FIIm, prothrombin mutation; CI, confidence 
interval.
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In addition, other clinical risk factors contribute to the thrombotic 
risk, including cardiac disease, malignancy, surgery, immobility, 
and medications such as asparaginase and estrogen-containing 
contraceptives. These clinical risk factors may trigger VTE 
in thrombophilia carrier patients. It is still a matter of debate 
whether it is useful to test thrombophilia in children with a first 
venous thrombotic event. This article will discuss the potential 
arguments for testing of inherited thrombophilia, including 
factor V Leiden mutation (FVL), prothrombin mutation (FIIm), 
and deficiencies of antithrombin, protein C, or protein S and 
suggests some pediatric patient groups, which may be candidates 
for testing.
inHeRiTeD THROMBOPHiLiA
Inherited thrombophilia is defined as an inherited coagulation 
disorder associated with an increased risk for thrombosis. The 
most frequent inherited thrombophilic defects include deficien-
cies of antithrombin, protein C, protein S, FVL, and FIIm.
Antithrombin deficiency was the first identified genetic risk 
factor for VTE. In 1965, Egeberg reported a family with increased 
risk for venous thrombosis due to antithrombin deficiency (6). 
He was the first who used the term thrombophilia. Antithrombin 
deficiency appears to be very scarce with a prevalence of about 
0.02% in the general population (7).
Antithrombin inhibits several enzymes of the coagulation 
system including factor IIa, IXa, Xa, and XIIa. Type I deficiency 
is associated with low antithrombin antigen and activity levels. 
Type II deficiency is characterized by decreased functional activ-
ity. Homozygous antithrombin deficiency type I patients have 
not been described, assuming complete antithrombin deficiency 
is not compatible with life.
Protein C and protein S act together to inactivate factor Va and 
factor VIIIa. Protein C deficiency has been recognized since 1981 
(8). Since then, more than 160 mutations have been identified. 
The prevalence of protein C deficiency is estimated to be about 
2% (7). Two types of protein C deficiency have been described. 
Type 1 deficiency is associated with decreased antigenic levels as 
well as functional activities of protein C. In type II deficiency, the 
activity levels of protein C are more decreased than the antigenic 
levels.
Protein S deficiency has first been described in 1984 (9). The 
prevalence is low and varies between 0.026 and 0.13% (7). Two 
forms of protein S are present in the plasma: about 60% is bound 
to complement regulator C4b-binding protein and the remaining 
40% circulates as free protein S. Only free protein S can serve as a 
cofactor for activated protein C. There are three types of protein 
S deficiency. Types I and III are quantitative deficiencies. In type 
I, levels of both free and total protein S are low, whereas only 
free protein S levels are decreased in type III deficiency. Type 
II deficiency is a qualitative disorder with normal antigen and 
decreased activity levels of protein S.
Both protein C and S deficiency can present in heterozygous, 
homozygous, or compound heterozygous forms, although the 
last two forms are extremely rare. These patients present with 
neonatal purpura fulminans (10, 11). In infancy, diagnosis of 
homozygous protein C or S deficiency can be made by measuring 
the functional activity of protein C or S, which will be undetect-
able. Diagnosis of heterozygous protein C, S, or antithrombin 
deficiency, however, will be challenging as all anticoagulant pro-
tein levels are physiologically lower in healthy (preterm) neonates 
compared to adult levels as result of developmental hemostasis 
(12). Protein S and antithrombin levels reach adult levels over 
the first 6 months of life. Protein C levels may remain low until 
adolescence (13).
FVL is the most common inherited thrombophilic defect 
although its prevalence varies widely. Prevalences of heterozygous 
FVL range from 1 to 9% in European countries, whereas it is rarely 
found in African and Asian individuals (14). FVL is characterized 
by a substitution of glutamine by arginine on position 506 of the 
factor V protein at the activated protein C cleavage site. It causes 
resistance of factor Va to cleavage by activated protein C leading 
to an excess of factor Va and, consequently, a hypercoagulable 
state (15, 16).
FIIm is the second most common inherited thrombophilic 
defect. In Caucasians, the prevalence of this mutation is about 2% 
(17). It is characterized by a point mutation (nucleotide 20210 G 
to A) in the prothrombin gene, which is associated with increased 
levels of prothrombin, the precursor of thrombin (18). Increased 
levels of prothrombin increase the half-life of factor Va. As factor 
Va, bound in the prothrombin-factor Va complex, is resistant to 
activated protein C cleavage, increased levels of prothrombin 
increase the half-life of factor Va, leading to a hypercoagulable 
state.
wHY SHOULD we TeST FOR inHeRiTeD 
THROMBOPHiLiA in CHiLDRen wiTH  
A FiRST venOUS THROMBOTiC evenT?
In general, there are three possible arguments to test for throm-
bophilia in children with a first venous thrombotic event. First, if 
there is an association between inherited thrombophilia and the 
development of pediatric thrombosis, identification of a throm-
bophilic defect may help to learn why a young patient developed 
thrombosis, especially if the thrombotic event was unprovoked. 
Second, testing should be performed if a positive test result will 
change the patient’s management, such as prolongation of anti-
coagulant prophylaxis of recurrent thrombotic events. Finally, 
testing pediatric patient with VTE may help to identify asympto-
matic relatives who may avoid thrombotic risk factors and benefit 
from thromboprophylaxis in high-risk situations.
Association between inherited 
Thrombophilia and venous Thrombosis
Patients, parents, and their doctors would often like to have an 
explanation for the VTE event. Several case series, case-control 
studies, registries, and cohort studies have been published, 
which studied the impact of inherited thrombophilia on VTE in 
children. In 2008, Young et al included these studies in a meta-
analysis, which showed that children with first-onset VTE were 
more likely to have inherited thrombophilia than controls (19). 
The odds ratios varied from 2.63 [95% confidence interval (CI), 
1.61–4.29] for FIIm to 8.73 (95% CI, 3.12–24.42) for antithrombin 
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deficiency. These ORs resembled the relative risks found in 
adults with VTE (20). So, in general inherited thrombophilia 
contributes to the development of VTE in children. Testing for 
thrombophilia might reveal one of the causes of the thrombotic 
event in a pediatric patient. The identification of a thrombophilic 
defect, though, does not exclude other risk factors as shown in 
the meta-analysis. More than 70% of the patients had at least one 
clinical risk factor, illustrating that a thrombophilic defect alone 
is usually not enough to develop pediatric thrombosis.
The association between inherited thrombophilia and 
certain patient subgroups is less clear. An important limita-
tion of the above-mentioned meta-analysis was that patient 
subgroups like provoked or unprovoked, neonatal VTE, and 
catheter-related VTE could not be analyzed separately due to 
small groups, and unclear definitions in the original studies. 
Nevertheless, other studies showed that the prevalence of 
inherited thrombophilia seems to be higher in adolescents with 
unprovoked thrombosis and in children with a positive family 
history for VTE and lower in children with cardiac disease 
or malignancy with catheter-related thrombosis (21–24). In 
neonates with catheter-related thrombosis, only a few small 
studies investigated the prevalence of thrombophilia defects, 
which were rarely found (25–27).
Thrombophilia and the Management  
of Thrombosis
A more important reason in favor of thrombophilia testing would 
be the need to adjust the management of thrombosis in case of a 
positive result. At the moment, the identification of an inherited 
thrombophilic defect does not alter the acute antithrombotic 
management in children (28). Whether the duration of antico-
agulation will change after discovery of a thrombophilic defect 
is dependent on the risk of side effects of anticoagulation, such 
as major bleeding, the risk of recurrent VTE and the preference 
of the patient. In adults, the annual incidence of major bleeding 
from long-term anticoagulation is 1.5–2% (29, 30).
Generally, the cumulative recurrence-free survival in chil-
dren is reported to be 92% after 1  year and 82% after 7  years 
of follow-up (24). Young et al. studied the association between 
inherited thrombophilia and recurrent VTE in children (19). 
Their meta-analysis showed a significant but mild association 
for all thrombophilic defects, except FVL. The ORs varied from 
2.15 (95% CI, 1.12–4.10) for FIIm to 3.76 (95% CI, 1.76–8.04) for 
protein S deficiency. Children with two or more thrombophilic 
defects had the highest risk for recurrent VTE (OR 4.91; 95% 
CI, 3.12–7.74). The thrombotic recurrence risk in children with 
thrombophilia was slightly higher than that in adults (Table 1). 
This might be caused by lack of prophylactic anticoagulation in 
high-risk situations after the first thrombotic event. In children, 
it was not common practice to administer thromboprophylaxis 
in high-risk situations such as immobility, surgery, or trauma. In 
adults as well as in children, the mild increased recurrence risk in 
patients with inherited thrombophilia has not lead to adjustment 
of the duration of anticoagulant therapy.
Very recently, Limperger et al. studied the annual recurrence 
rate of pediatric patients after a first non-catheter-related VTE 
(31). In general, the estimated risk of VTE recurrence was 1.5% 
per year. In children with high-risk thrombophilia, the annual 
recurrence rates were 5.4% (95% CI, 2.6–10%) in children with 
antithrombin deficiency, but only 1.3% (95% CI, 0.3–3.8%) and 
0.7% (95% CI, 0.08–2.4%) in protein C and protein S deficient 
patients, respectively. In patients with no thrombophilia, the 
annual recurrence rate was 0.9% (95% CI, 0.4–1.8%). Thus, based 
on these results, particularly antithrombin-deficient patients have 
an increased recurrence risk. These patients might be identified 
by testing and benefit from preventive strategies.
These preventive strategies may include indefinite anticoagu-
lation with vitamin K antagonists or intermittent anticoagulation 
in high-risk situations. Both strategies have not been studied in 
children yet. As in the study of Limperger et al., 9 out of the 10 
children with antithrombin deficiency had provoked recurrent 
VTE, the latter strategy with intermittent anticoagulation might 
be sufficient enough to prevent recurrent VTE with less risk of 
bleeding. One might argue, however, that every young patient 
should get intermittent prophylactic anticoagulation in high-risk 
situations after a first VTE, independent from the presence of 
inherited thrombophilia. Due to decreased bleeding risk, the 
new direct oral anticoagulants might appear to have a favorable 
benefit-to-risk ratio for prolonged anticoagulation in children 
with antithrombin deficiency in future.
identification of Asymptomatic Relatives
It is suggested that inherited thrombophilia testing in pediatric 
patients with VTE allows the identification of asymptomatic 
family members with thrombophilia. The affected relatives will 
have the opportunity to avoid risk factors such as smoking and 
obesity to get informed about thrombotic risks of contraception 
and pregnancy and to use thromboprophylaxis in high-risk 
situations.
Holzhauer et al. investigated the general, annual incidence of 
VTE in first- and second-degree relatives of pediatric patients 
with VTE and inherited thrombophilia (32). The absolute risk of a 
first thrombotic event per year in asymptomatic relatives was not 
very high. It was higher in carriers of antithrombin, protein C or S 
deficiency (2.82%; 95% CI, 1.63–4.80%) than in carriers of 
FIIm or FVL (0.42%; 95% CI, 0.17–1.01% and 0.25%; 95% CI, 
0.12–0.53%), respectively. In relatives without inherited throm-
bophilia, the absolute VTE risk per year was 0.10% (95% CI, 
0.06–0.17%). As in adults, the inherited thrombophilic defects 
can, therefore, be divided in low-risk thrombophilia, including 
FVL and FIIm and high-risk thrombophilia, including deficien-
cies of antithrombin, protein C or S (32, 33). Remarkably, almost 
65% of VTE in the first- and second-degree relatives of pediatric 
VTE patients with thrombophilia in the study of Holzhauer et al. 
was associated with clinical risk factors. Thus, discussion with 
asymptomatic relatives about avoidance of lifestyle risk factors 
such as obesity and smoking and eventually thromboprophylaxis 
in high-risk situations might be enough to prevent most VTE, 
regardless of inherited thrombophilia status.
Screening has been recommended for adolescents at fertile age 
with a family history of thrombosis and/or thrombophilia before 
start of oral contraceptives (34). Combined oral contraceptives 
are an important risk factor for VTE. The thrombotic risk is much 
TABLe 1 | Association-inherited thrombophilia with risk of vTe in children.
Prevalence (%) 
(population)
Summary OR (95% Ci) first 
vTe (19)
Summary OR (95% Ci) 
recurrent vTe (19)
Annual risk (%, 95% Ci) 
for recurrence after non-
CvC-related vTe (31)
Annual risk (%, 
95% Ci) for vTe 
in asymptomatic 
carriersa (32)
Antithrombin deficiency 0.02 8.73 (3.12–24.42) 3.37 (1.57–7.20) 5.4 (2.6–10)
2.82 (1.63–4.80)Protein C deficiency 0.2 7.75 (4.48–13.38) 2.53 (1.30–4.92) 1.3 (0.3–3.8)
Protein S deficiency 0.03–0.13 5.77 (3.07–10.85) 3.76 (1.57–8.04) 0.7 (0.08–2.4)
Factor V Leiden 3–7 3.56 (2.57–4.93) 0.77 (0.40–1.45) 0.25 (0.12–0.53)
Prothrombin mutation 1–2 2.63 (1.61–4.29) 2.15 (1.12–4.10) 0.42 (0.17–1.01)
aFirst- or second-degree relative of pediatric patient with venous thromboembolism (VTE) and thrombophilia.
OR, odds ratio; CI, confidence interval; CVC, central venous catheter.
TABLe 2 | Arguments pro and contra thrombophilia testing in children 
with venous thromboembolism (vTe).
Arguments pro thrombophilia 
testing
Arguments contra thrombophilia 
testing
Association between inherited thrombophilia and vTe in children
Explanation of pathophysiology, 
especially if VTE was unprovoked
Most pediatric patients have at least 
one clinical risk factor, illustrating that a 
thrombophilic defect alone is not enough to 
develop VTE
It is unclear whether the association is valid 
for all patients groups, for example, children 
with catheter-related thrombosis
Management of vTe in children
Prediction of recurrence risk 
and opportunity for prophylactic 
anticoagulation in high-risk 
situations, especially in patients 
with antithrombin deficiency
All children should get prophylactic 
anticoagulation in high-risk situations after 
first VTE
Efficacy of prophylactic strategies have not 
been studied in children
identification of asymptomatic relatives with inherited thrombophilia
Instruction about signs and 
symptoms of VTE to accelerate 
diagnosis and avoidance of 
thrombotic risk factors, such as 
obesity and smoking
Testing is not necessary to instruct patient 
and family members about signs and 
symptoms of VTE and to avoid thrombotic 
risk factors
Opportunity for prophylactic 
anticoagulation in high-risk 
situations, especially in patients 
with high-risk thrombophilia
As most VTE in affected family members 
are provoked, thromboprophylaxis in high-
risk situations might be enough to prevent 
VTE
Counseling about combined oral 
contraceptives in asymptomatic 
female carriers with thrombophilia
False reassurance if thrombophilia testing 
is negative
Consider alternative contraceptive in all 
women with first-degree relative with VTE, 
without testing
In general: psychological distress of 
knowing to be a carrier and difficulties to 
obtain health or life insurances
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higher in women with high-risk than with low-risk thrombo-
philia. The annual thrombotic risk on combined oral contracep-
tives is 4.3% for asymptomatic carriers with a positive first-degree 
relative with VTE and high-risk thrombophilia. The risk is only 
0.2–0.5 per year of use for asymptomatic carriers with a positive 
first-degree relative with VTE and low-risk thrombophilia (35). 
As a consequence, it may be worthwhile to test adolescents from 
families with high-risk thrombophilia to avoid use of combined 
contraceptives. However, in case of strong family history for VTE, 
combined contraceptives should be avoided in asymptomatic 
carriers of low thrombophilia, as well. When counseling these 
patients, it is important to realize that in families with a family 
history for VTE and/or thrombophilia, the thrombotic risk is 
also increased in unaffected relatives, due to yet unknown genetic 
variables and/or clinical risk factors (35). Consequently, negative 
thrombophilia testing may cause false reassurance. Therefore, 
some guidelines advise to consider an alternative contraceptive 
in women with a first-degree relative with VTE, independent of 
testing (36).
DiSADvAnTAGeS OF TeSTinG
One of the disadvantages of testing children with VTE could be 
the psychological stress of knowing to be a carrier of an inherited 
thrombophilic defect. No studies are available investigating the 
psychological impact of thrombophilia testing on children. In 
adults, thrombophilia testing does not seem to trigger psycho-
logical stress or worry (37, 38). Another disadvantage may be 
the potential problems with health insurance or life insurance in 
future. One of the patients in the study of Bank et al. had been 
discriminated by an insurance company because of FVL. The 
other 16 patients had not informed the insurance companies 
(39). Finally, thrombophilia testing is expensive. Many tests are 
ordered inappropriately (40, 41). Proper thrombophilia testing 
will reduce costs.
wHO SHOULD we TeST FOR inHeRiTeD 
THROMBOPHiLiA in CHiLDRen wiTH  
A FiRST THROMBOTiC evenT?
As mentioned before, the chance of finding inherited throm-
bophilia varies between pediatric patient groups with VTE. 
Inherited thrombophilia seems to be present in adolescents with 
unprovoked thrombosis and children with a positive family his-
tory. In the study of Revel-Vilk et al., thrombophilia was detected 
in only 13% of all 171 pediatric patients with VTE, but in 60% 
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of the adolescents with unprovoked thrombosis (22). Ruud et al. 
showed in a cross-sectional study that a positive family history 
for VTE increased the relative risk of a child having inherited 
thrombophilia to 2.35 (95% CI, 1.1–5.2) (42). In addition, in a 
prospective cohort study of 100 neonates and children with VTE, 
positive family history appeared to be the only predictor for 
presence of inherited thrombophilia (OR 14.9; 95% CI, 1.9–113) 
(24). In neonates and children with catheter-related thrombosis, 
thrombophilia was found less frequently. For example, Salonvaara 
et  al. described 10 neonates with symptomatic catheter-related 
thrombosis. Only 1 of the 10 patients had FVL (26). Albisetti et al. 
studied the prevalence of thrombophilia in cancer patients with 
and without catheter-related thrombosis. Thrombophilia was 
found in 4% of cancer patients with VTE and in 12% of patients 
without VTE (21). Finally, Thom et al. could not find an associa-
tion between catheter-related VTE and thrombophilia in cardiac 
pediatric patients (23).
So, thrombophilia testing seems to be advisable in adolescents 
with unprovoked VTE and in children with a positive family his-
tory for VTE and less useful in neonates and children after a first 
episode of catheter-related VTE.
SUMMARY
The presence of inherited thrombophilic defects in neonates and 
children with a first event of VTE does not influence primary 
antithrombotic management and while it may be one of the 
causes of the thrombotic event, it infrequently alters long-term 
management. However, the presence of antithrombin deficiency 
with its high risk of recurrent thrombosis may warrant adjustment 
of long-term management. In these children, intermittent anti-
coagulation in high-risk situations may aid to prevent recurrent 
thrombotic episodes. Furthermore, testing might be helpful to 
identify asymptomatic female relatives with thrombophilia who 
may get better informed about a healthy lifestyle and the risks of 
combined oral contraceptives at fertile age.
On the other hand, one might argue that all children with first 
VTE are candidates for prophylactic anticoagulation in high-
risk situations, not only antithrombin deficient children. And a 
positive family history for VTE might be enough to choose less 
thrombotic contraceptive methods, such as progesterone-only 
preparations (Table 2).
Consequently, testing for inherited thrombophilia in children 
with a first episode of VTE should not be performed on a routine 
basis. In neonates and children with catheter-related thrombosis, 
inherited thrombophilia seems to contribute less to the throm-
botic event than in adolescents with unprovoked thrombosis 
and children with a positive family history for VTE. Therefore, 
especially these latter groups seem candidates for testing.
In these children, the decision of testing should be made on 
an individual base after proper counseling before and after testing 
by an experienced physician, discussing the disadvantages and 
benefits of testing, the preference of the patient, and the conse-
quences of the test results after testing.
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